Aslan Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(5.7%),Lind Global Partners II LLC(5.7%), etc.
Aslan Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(5.7%),Lind Global Partners II LLC(5.7%), etc.
Aslan Pharmaceuticals | SC 13G:超過5%持股股東披露文件-Lind Global Fund II LP(5.7%),Lind Global Partners II LLC(5.7%)等
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。